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Bioimprint aided cell recognition and depletion of human 
leukemic HL60 cells from peripheral blood 
Anupam A.K. Das,a Jevan Medlock,a He Liang,a Dieter Nees,b David J. Allsup,c Leigh A. Maddend and 
Vesselin N. Paunov*a
We report a large scale preparation of bioimprints of layers of 
cultured human leukemic HL60 cells which can perform cell shape 
and size recognition from a mixture with peripheral blood 
mononuclear cells (PBMCs). We demonstrate that the bioimprint-
cell attraction combined with surface modification and flow rate 
control allows depletion of the HL60 cells from peripheral blood 
which can be used for development of alternative therapies of 
acute myeloid leukaemia (AML).
AML is a clonal malignant proliferation of transformed, bone-
marrow derived myeloid precursors. The disease is 
characterised by the rapid proliferation of the neoplastic cells 
(myeloblasts) resulting in failure of normal haematopoiesis with 
consequential bone marrow failure rapidly resulting in death if 
untreated.1-3 In the UK, overall survival is 16% 5 years from 
diagnosis. The prognosis is significantly worse in the elderly 
which is especially relevant as the majority of patients present 
over the age of 60 years.1,4-7 Therapy relies on 2–3 cycles of 
myeloablative chemotherapy followed by allogeneic stem cell 
transplant for a relatively small number of fit patients with poor 
prognostic features.8-9 This is accompanied with significant 
discomfort, long therapy for AML also is associated with 
prolonged inpatient stays, considerable morbidity related to 
anaemia, sepsis and bleeding and an attributable mortality of 5-
10%. The majority of patients relapse following induction of 
chemotherapy for AML and subsequent therapy is associated 
with a low probability of success. Outcomes for AML patients 
have improved marginally over the past few decades, largely 
due to improvements in supportive care rather than dramatic 
improvements in the chemotherapeutic regimens efficacy.10 
Bioimprinting is a promising area of materials chemistry aimed 
to mimic and exploit the lock-and-key interactions seen 
ubiquitously in nature.11-14 
Figure 1. Schematic representation of the method of action of the flow through 
bioimprint chip for depletion of myeloblasts from peripheral blood.
Cell recognition systems are relatively cheap and simple to 
produce with few stipulations on storage and shelf life when 
compared with biological interventions. The scope for possible 
targets is also much greater, being able to target 
polysaccharides, enzymes, aptamers, DNA sequences, 
antibodies and whole cells.12,15,16, 21-24 Bioimprints of whole cells 
were first reported by Dickert et al.17 who imprinted yeast into 
a sol-gel matrix. When incubated with several strains of yeast, 
the substrates showed a high affinity to the template material. 
This effect was attributed to the large contact surface areas 
between cells and the imprinted cavities. Other cell 
bioimprinting studies have progressed to cover a range of 
micro-organisms and human cells. Hayden et al.18
functionalised polyurethane with erythrocyte imprints, capable 
of discriminating between ABO blood groups. Though all cell 
targets possessed the same geometrical size and shape, 
imprints were able to discriminate on account of varied surface 
antigen expression. Subsequent studies were further able to 
discriminate cells with identical antibodies in different 
quantities to separate blood groups A1 and A2.19 Recent cell 
bioimprint studies largely focus on biosensor applications20,26 
and are hindered by the small overall size of imprinted areas 
that can be produced which limits their applications for large 
scale extraction of targeted cell from cell mixtures. This 
research area is undergoing a rapid expansion towards using 
molecularly imprinted polymers as receptor mimics for 
selective cell recognition and sensing, a recent review of size 
and shape targeting of cancer found no evidence so far of the 
use of cancer bioimprints in a therapeutic setting.11 
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Figure 2 Schematic showing the preparation of negative and positive bioimprints from myeloblast cell layers by subsequent templating with curable silicone (PDMS) and photo-
curable polyurethane (PU) resin, respectively.  (b) Schematics showing our tool for spreading the HL60 cells aqueous suspension on glass to yield a uniform cell layer of large area.
Here we utilised for the first time AML cell bioimprints on a large 
scale as a vehicle to selectively target AML myeloblasts due to 
the inherent size and morphological discrepancies with normal 
peripheral blood mononuclear cells (PBMCs) (see Figure S1, 
ESI). We explore AML bioimprinting as a new method for 
depletion of myeloblasts from peripheral blood cells by 
introducing selectivity via bespoke cell size and shape 
discrimination aided by myeloblast-bioimprint interactions. Our 
idea is based on incorporating AML myeloblast-imprinted 
substrates into a flow-through type of device which offers an 
alternative method for removal of the leukemic burden directly 
from patient aspirate. Successful leukophoresis can potentially 
be used more frequently in the extraction of myeloblasts from 
peripheral blood which is critical in stabilizing AML patients with 
leukostasis associated with hyperleuocytosis. By reducing the 
number of circulating tumour cells, the likelihood of early 
relapse is also diminished.25 
HL60, an immortalized leukemic cell line derived from an AML 
patient, was used as a very good proxy for primary (patient 
derived) myeloblast cells throughout our study due to their 
availability and ease of culture. Here we show how the desired 
HL60 cell bioimprints were produced from HL60 cell layers. We 
also discuss the integration of the produced myeloblast imprint 
in a PDMS-based flow-through cell, in which its selectivity 
towards HL60 cells over the PBMCs is investigated (Figure 1). 
We fabricated bioimprints by impressing a layer of cultured 
HL60 myeloblasts with a curable polymer, which captures 
information for the cells shape, size and morphology. These 
were further casted with another polymer to create a “positive 
imprint” whose surface matches the original cell layer. Using 
roll-to-roll printing from the positive replica we produced a very 
large area of HL60 cell imprints. We engineered the surface of 
the bioimprint to have a weak attraction with the cells, which is 
strongly amplified when there is a shape and size match 
between the individual cells and the imprinted surface. Due to 
inherent size and morphology differences between myeloblasts 
and normal blood cells, this resulted in much higher retention 
of the former on the bioimprint. This allows their selective 
trapping from peripheral blood based on cell shape and size 
recognition, much cheaper than using surface functionalisation 
with a combination of specific antibodies for myeloblasts. We 
tested the bioimprints selectivity in a device for depleting 
cultured HL60 cells from healthy white blood cells. This cell 
recognition technology can potentially deplete myeloblasts 
from the blood of AML patients and provide an alternative route 
for reducing the counts of the minimal residual disease, which 
is associated with reduced relapses and improved patient 
outcomes. 
Cell handling. All live cell cultures and handling were carried out 
aseptically in a biosafety cabinet class II with laminar flow 
(Thermo Scientific). The HL60 cell line (Public Health England, 
cat. 98070106) was used as a surrogate myeloblast throughout 
the study. These were cultured aseptically in Roswell Park 
Memorial Institute Medium (RPMI) 1640 (Gibco), containing 10 
vol% foetal bovine serum (Gibco), 5 mL penicillin and 5 mL 
streptomycin solutions at 37°C with 5% CO2. Primary peripheral 
blood mononuclear cells (PBMCs) were obtained from 
anonymous healthy donors via the NHS blood transfusion 
service (under IRAS 214660) and stored in liquid nitrogen prior 
to use. The cells were slowly defrosted and washed 3 times in 
phosphate buffer saline solution (PBS, from Sigma-Aldrich). 
Removal of platelets contamination was achieved by 
centrifugation at 120g for 10 min and resuspension in PBS, 
repeated three times. Cell fixation was carried for both HL60 
and PBMCs (at concentration 107 cells ml-1) by dropwise 
addition of the cell suspension to a stirred 0.5 v/v% 
glutaraldehyde (Sigma-Aldrich) in PBS solution. After 20 min., 
cells were washed by centrifugation at 400g for 4 min and re-
suspended in PBS. All fixed cells were washed three times with 
PBS and stored at 4 °C until further use. 
Bioimprint fabrication. The detailed schematic showing the 
production of the negative PDMS and positive PU based master 
HL60 myeloblast bioimprint is showed in Figure 2a. 
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Figure 3. Bright field microscope images of (a) negative and (b) positive HL60 bioimprints, scanning electron microscopy images of (c) negative and (d) positive HL60 bioimprints and 
atomic force microscopy images (e) negative and (f) positive HL60 bioimprints. All Scale bars are 50 µm.
Glass substrates (70 cm  40 cm) were cleaned with acetone 
and 10% KOH (Sigma Aldrich) in ethanol  for 1 h, rinsed with 
deionized water and treated with 20 wt% v/v 
poly(diallyldimethylammonium chloride) (PDAC) aqueous 
solution for 30 min. The substrates were further cleaned with 
deionized water and dried using compressed air. A sample of 
glutaraldehyde-fixed HL60 cells (6 g wet weight) and glucose 
(2.5 g) was mixed together in 30 mL of 0.1% (w/v) % xanthan 
gum solution. Spreading of this HL60 cell suspension on the 
glass substrate was done using a bespoke glass tool comprised 
of a square frame made of four glass strips, one of which was 
offset by 100 µm to create a gap. Figure 1b shows for the design 
and method of action of the spreading tool. The HL60 cell 
suspension was added to the frame interior and the device was 
moved along the glass substrate in one continuous motion in 
the direction opposite to the higher side, allowing an aqueous 
film of cell suspension (40 cm  70 cm) of uniform thickness 
(~100 m) to be deposited (Figure S2a, ESI). The aqueous film 
was allowed to evaporate to a semi-dry state at room 
temperature, done in a laminar flow cabinet to reduce any 
contamination (Figure S2b, ESI). Curable PDMS was made 
mixed at a 10:1 ratio of Sylgard 184 elastomer to accelerator 
and degassed by centrifugation (4000g, 10 min). A metal frame 
(interior space 65304 cm) was added around the deposited 
cell smear and the PDMS (900 mL) poured evenly inside. To 
provide structural support, a polyester fabric sheet (Boyes UK, 
dimensions 65×30×0.1 cm) was added on top of the PDMS layer 
and allowed to cure at room temperature for 48 h (Figure S2c, 
ESI). Cured PDMS bioimprints were removed from the glass 
surface and washed using warm water, detergent, ethanol and 
finally deionized water and then dried using compressed air. 
The negative PDMS based bioimprint (Figure S2d, ESI) was 
then copied onto a transparent polyethylene terephthalate 
(PET) foil with a pre-deposited layer of photo-curable PU-acrylic 
resin (supplied from Joanneum Research FmbH, Graz, Austria) 
under three 365 nm 10W portable UV lamps for 10 min (Figure 
S2e, ESI) to produce a positive bioimprint (Figure S2f, ESI). 
Multiple copies of positive HL60 bioimprints (62.9cm25cm 
shims) were made using the aforementioned process.
Replication of bioimprints by Roll-to-Roll (R2R) printing. Roll-
to-Roll nanoimprinting from sim made of the positive PU-acrylic 
resin on PET bioimprint shim was carried out by using Nano-
Imprinting Lithography (R2R NIL) in collaboration with 
Joanneum Research FmbH. Herein, the positive shim imprint 
(60cm  25cm) was mounted to the circumference of the 
imprinting shim of the R2R NIL printer where it was rolled and 
pressed against an incoming PET foil pre-coated with a film of 
UV curable acrylic resin and simultaneously cured by UV light in 
real time.27 R2R NIL printing was done at a rate of 1 m s-1 for a 
user defined length (see more detail in Figure S3, ESI) to 
produce acrylic-resin-based negative imprints of myeloblast 
layers on clear PET foil of 20 cm width. The R2R NIL replication 
yielded negative HL60 bioimprints, typically with a length of 
several hundred metres, before any visible erosion of the 
master positive imprint was detected.
Bioimprint surface modification. The negative HL60 
bioimprints replicated on a large scale via R2R nanoimprinting 
on PET foil were further surface functionalised to incur a weak 
attraction between target myeloblasts and bioimprints.
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Figure 4 (a) Graph showing the retention of the HL60 cells on HL60 bioimprints pre-treated with different concentration of bPEI followed by treatment with 1 wt% P407. (b) Schematic 
showing the trapping of HL60 cells on the HL60 imprint. Optical and overlapped fluorescence microscope image of imprints containing (c) 5 million, (d) 7.5 million and (e) 10 million 
HL60 cells mL-1. The bioimprint becomes saturated above 10 million HL60 cells mL-1. All Scale bars are 100 µm.
The imprints were first exposed to oxygen plasma (Harrick 
Plasma PDC 32G) at 147 Pa, using an RF power of 16 W for 4 
min. The plasma treated imprint was further layered using a 
glass rod with branched polyethylene imine (bPEI) – see ESI for 
more details. The imprint was incubated with bPEI solution for 
20 min, then submerged in deionized water, gently stirred for 5 
min, then rinsed with deionised water and dried in air stream.
HL60 cells/PBMCs fluorescence staining. The fixed cells were 
fluorescently labelled to allow numeration and identification of 
the type of cells retained on the HL60 negative bioimprints. 
HL60 cells were stained by dropwise addition of 100 µL of 
0.025% (w/v) 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine 
N(carboxyfluorescein) in ethanol. PBMCs were stained via a 
similar method using 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine-N (lissamine rhodamine B sulphonyl) 
(ammonium salt). The excess dye was removed by multiple 
washing and replacing the media with PBS using centrifugation 
at 400g for 5 min. An Olympus BX51 microscope coupled with a 
mercury lamp excitation source and DP70 camera (Olympus) 
with ImageProPlus software was used to capture images of the 
captured cell populations retained on the HL60 bioimprint. 
Flow-through bioimprint chip fabrication. The bPEI-treated 
bioimprints were incorporated into flow-through chips made 
from a glass slide and a moulded PDMS channel. PDMS strips 
(361 cm) were made yielding an exposed channel (0.540.1 
cm) which was punctured to allow inlet and outlet tubing to be 
fed (internal diameter 1 mm). The PDMS substrate and a clean 
glass microscope slide were treated in oxygen plasma (32 W, 
147 Pa) for 3 min. A stripe of the surface functionalised 
bioimprint (0.5cm  4 cm) was trapped between the activated 
glass slide and covered with pre-fabricated PDMS block, with 
the bioimprint fixed in the moulded channel. The schematic of 
the flow chip is shown in Figure 1 and the photographs of the 
produced PDMS based chips are shown in Figures S4a and S4b, 
ESI. The chip was clamped to ensure a tight seal and cured at 
40°C for 30 min to bind the glass to the PDMS block. The chip 
with the embedded HL60 bioimprint was loaded with 200 μL of 
1% or 3% (w/v) aqueous solution of Poloxamer 407 (Sigma-
Aldrich) and incubated for 20 mins prior to the cell-selectivity 
experiments. This was done to reduce the non-specific cell 
adhesion on the PDMS channel, the bioimprint and the tubing. 
Syringe pump was used to pre-wash the chips, passing 10 mL of 
PBS through the chip at a rate of 225 mL/h. 
HL60 and PBMCs cell retention experiments. Retention of fixed 
HL60 cells was investigated as a function of the HL60 cell 
concentration seeded over the imprint for a range of substrate 
functionalization parameters. Suspensions of fluorescently 
tagged, fixed HL60 cells in PBS (100 µL) were made at a range of 
concentrations. Cell samples were injected into flow-through 
chips containing the surface treated HL60 negative bioimprints 
and incubated for 1 h. Inlet and outlet tubing (internal diameter 
1 mm) were fitted to opposite ends of the chamber containing 
the bioimprint. Unbound cells were washed off the bioimprint 
using a syringe pump by elution with 10 mL PBS at a fixed flow 
rate. Retention of HL60 cells was assessed by using a 
combination of bright field and fluorescence microscopy at 
various sites across the bioimprint (20 fields of view). The static 
condition experiment is shown in Figure 1. Cells were 
numerated by using fluorescence microscope images collected 
using both FITC filter set (showing HL60 as green) and TRITC 
filter sets (showing PBMCs as red) in order to separately assess 
each cell type collected on the bioimprint. To separate 
conjoined cells, the watershed feature was used in ImageJ. A 
lower boundary of cell size was used to prevent fluorescent cell 
fragments and debris from being counted as a whole cell, this 
was found from analysis of fluorescently tagged cell 
populations. Results were compared as the average number of 
cells per metre squared, hereafter termed the cell area density.
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Figure 5. Bright field with fluorescence overlapped microscope images (a) showing the retention of the HL60 (green) and PBMC (red) cells on an un-imprinted flat PU-coated slide 
and (b) on bioimprint functionalised with 0.015 wt %bPEI and 1 wt% Poloxamer 407. (c) The retention of the HL60 and PBMCs on the bioimprint vs cell seeding concentration.
The Image J macro used for this function is enclosed in the ESI. 
AML poses a difficult target for conventional biological assays 
owing to a heterogeneous antigen expression and sheer 
abundance of neoplastic material. However, the fluid nature of 
the malignancy and size discrepancy between healthy and 
cancerous tissue was targeted by a bioimprint. The size 
differences can be seen in Figure S1a and S1b, ESI showing live 
bright field optical microscopy images of a sample of typical 
HL60 cells and PBMCs. Flow cytometry data show that the HL60 
cells are ~47% larger than the average size of the PBMCs, i.e. 
there is a large size disparity between PBMCs and HL60 cells. All 
cells were chemically fixated using glutaraldehyde prior to use 
to prevent deformation and damage during the imprinting 
process. For consistency we did the selectivity experiments with 
the same batches of fixed cells. The bright field microscopy 
images of glutaraldehyde fixed HL60 cells and PBMCs is shown 
in Figures S1c and S1d, showed similar surface morphology and 
cell shape information. Optical microscopy image of the 
negative PDMS-based HL60 cell imprint, copied directly from 
the HL60 cell layer, is shown in Figure 3a, while the positive PU-
based replica is represented by Figure 3b, 3d and 3f with bright 
field, SEM and AFM images, respectively. SEM and AFM images 
of the resultant negative PU-based HL60 bioimprint produced 
by replicating of the positive shim and used for trapping the 
HL60 cells in the microfluidic device are shown in Figure 3c and 
3e, respectively. These samples of bioimprints were produced 
with the NIL R2R printing according to the procedure described 
above. Further surface treatment of the negative HL60 
bioimprint was aimed to introduce a weak attraction between 
the imprint and the negatively charged HL60 cells. This was 
achieved by additional surface treatment of the produced 
imprint on PET foil by oxygen plasma which oxidizes the resin 
surface and creates carboxyl surface groups which serve as 
adsorption sites for the subsequent treatment with a cationic 
polyelectrolyte (bPEI), whose adsorption makes the bioimprint 
surface cationic. The cell surfaces are normally negatively 
charged due to the presence of COOH groups from 
carbohydrates and glycoproteins on their cell membranes.28 As 
the adhesion force of the cells to the bioimprint depends on the 
contact area between them, cells that better match the 
imprinted cavities are stronger attached to its surface. Since 
PBMCs are much smaller than the HL60, the former would only 
interact with the imprint surface in a “point contact” which 
leaves them weakly bound. On the other hand, the HL60 cells 
better match the HL60 imprint cavities which leads to full 
contact between the imprint surface and a large portion of the 
HL60 outer cell membrane. Above certain specific flow rate, the 
flow in the chip would “flush off” the weakly bound PBMCs 
while the HL60 cells remain trapped on the imprint. 
In order to increase the selectivity of the bioimprint and reduce 
non-specific binding of PBMCs on the imprint, the chip channels 
and the adjacent tubing, surfaces were further passivated with 
a Pluronic surfactant (Poloxamer 407) which is a three-block 
co-polymer with one hydrophobic group in the middle 
(polypropylene oxide) and two on each side that are hydrophilic 
(polyethylene oxide). The Poloxamer 407 coating also minimizes 
the close contact between the cells and the bPEI coating. We 
tested several different concentrations of the cationic 
polyelectrolyte (bPEI), the Poloxamer 407 concentration and 
varied the flow rates in order to improve the bioimprint and 
chip selectivity with respect to retention of the HL60 cells. This 
was done in order to improve the bioimprint selectivity for HL60 
compared to PBMCs where the cells mixture was incubated in 
the chip and later flushed with PBS at different flowrates.
Theoretical calculations have shown that the substantial 
increase of the area of contact between the cell imprint and a 
matching cell in the near vicinity can increase the energy of even 
a weak cell-surface attraction by several orders of magnitude.24 
We found that the retention of the HL60 cells on the imprint 
increased with the increase in the bPEI concentration used to 
pre-treat the HL60 cell bioimprint, as shown in Figure 4a. The 
resulting graph resembles an adsorption isotherm for these 
cells on the bioimprint surface at fixed flow rate, where the 
increase of HL60 seeding concentration leads to occupation of 
more surface cavities on the bioimprint (see Figure 4b). The 
number of HL60 cells captured on the HL60 imprint increases 
with the increase in their seeding concentration (see Figures 4c, 
4d and 4e. The imprint was completely saturated above HL60 
seeding concentration of 106 cells mL-1.
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Figure 6. The percentage of decrease of the HL60 cells and PBMCs on the negative HL60 bioimprint after flushing the chip with PBS at different flowrates. The bioimprint was treated 
with (a) 0.015% and (b) 0.01 wt% bPEI with 1 wt% Poloxamer 407 functionalised and the corresponding HL60 selectivity of the bioimprint (in %) in (c) 0.015 wt% and (d) 0.01 wt% 
bPEI, respectively at the same conditions. (e) The percentage decrease of HL60 and PBMC after flushing at 150 ml/hr flowrate and (b) the selectivity of the HL60 imprint towards 
HL60 (in %) on imprints treated with 0.015% bPEI and functionalised by incubation with aqueous solutions of different concentrations of Poloxamer 407.
Note that the amount of retained HL60 cells at fixed flow rate 
depends on the cationic polyelectrolyte concentration used to 
pre-treat the bioimprint. However, we found that very low bPEI 
concentration (0.015 wt%) leads to almost full saturation and 
further increase does not significantly increase the retained 
HL60 amount (cf. Figure 4a at bPEI 1 wt%). It was also observed 
that the flat (non-patterned) PU surface has no selectivity 
compared to the HL60 bioimprint as shown in Figures 5a and 5b. 
The experiment was also conducted using PBMCs which showed 
minimum adhesion as evident from the curve in Figure 5c.  In 
order to check the selectivity of the HL60 cells over the PBMCs 
for HL60 imprint, a model mixture of HL60 and PBMCs at fixed 
HL60:PBMCs ratio of 20:80 was prepared in PBS and incubated 
on the imprint pre-coated with desired amount of bPEI and pre-
treated with Poloxamer 407. After 1 hour of incubation the chip 
was flushed with PBS at a range of flowrates. It was found that 
in both cases where the HL60 imprints were treated with 0.01 
wt% and 0.015 wt% bPEI showed more efficient HL60 retention 
compared to PBMC as evident from Figures 6a and 6b, 
respectively at all flowrates ranging from 70 mL/h to 225 ml/h. 
The percentage decrease of HL60 and PBMC cell after flushing 
of the chip and the bioimprint selectivity with respect to HL60 
cells are calculated as described in ESI. The highest amount of 
HL60 compared to PBMC was retained in case of the imprints 
coated with the combination of 0.015 wt% bPEI, 1 wt% 
Poloxamer 407 and flushed with PBS at a flowrate of 150 ml/h 
as shown in Figure 6a. Among all the combinations tested it was 
found that imprint coated with 0.015 wt% PEI, 1 wt% Poloxamer 
407 and flushed with PBS at a flowrate of 150 ml/h showed the 
largest selectivity potential and hence was used for further 
experiments. These results were also reflected in Figures 6c and 
6d where the percentage of HL60 increased compared to the 
PBMCs before and after flushing the chip with PBS. The effect 
of the Poloxamer 407 concentration was also evaluated on the 
imprint selectivity towards the HL60 cells. Without Poloxamer 
407 treatment the imprint retained comparable amounts of 
PBMCs and HL60 as evident from Figures 6e and 6f due to strong 
non-specific adsorption at this flowrate. The additional coating 
of the imprint with 1% and 3% Poloxamer 407 in two different 
cases showed preferential HL60 retention (Figure 6e and 6f). 
Note that the PBMCs have much higher percentage of decrease 
on the imprint than the HL60 cells, which predominantly remain 
on the bioimprint after the flushing step. These results call for 
some discussion. The initial idea was to modify imprint surface 
to attract the negatively charged target cells (HL60). As the 
PBMCs are also negatively surface charged cells, it was 
important to have a weaker attraction for the PBMC compared 
to the HL60. This was done by cell shape and size recognition 
where the cell adhesion is amplified by substantial surface area 
of contact between the cells and the imprint.24 The weak and 
relatively short-range attraction can be increased by several 
orders of magnitude by simply getting the surface area of 
contact maximized and selectively flushing out cells with 
smaller area of contact (PBMCs) compared to the larger HL60 
which better fit the bioimprint cavities. The role of the 
Poloxamer 407 was to passivate the bioimprint surface and to 
slightly offset the minimal distance of approach of PBMCs, 
which would minimise the non-specific adhesion of these cells 
to the imprint and weaken their attachment. Although the 
Poloxamer 407 coating had the same effect on HL60 cells, their 
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larger contact area upon cell shape and size recognition by the 
matching imprint cavities yields much higher force of 
attachment which makes possible the discrimination between 
HL60 and PBMCs by the bioimprint.
In summary, we showed that bioimprints of cultured HL-60 
cells, representative of patient derived myeloblasts can be 
produced efficiently using the process of casting cell layers with 
curable resins which copy part of the cell surface and retains 
information about their size, shape and surface morphology on 
the imprint. The cell imprint in curable silicone (PDMS) were 
subsequently copied onto a positive replica from UV-curable 
polyurethane (PU)-acrylic resin and reproduced on a very large 
scale using the Roll-to-Roll NIL printing. The negative HL60 
bioimprints were then successfully integrated into a PDMS-
based flow-through chip and tested to explore the HL60 
retention capacity and selectivity in a mixture with PBMCs. It 
was found that these bioimprints do have a specificity for the 
HL60 cells when the surfaces were pre-treated with a cationic 
polyelectrolyte (bPEI) and Poloxamer 407. It was also concluded 
that Poloxamer 407 treatment improves the bioimprint 
selectivity towards HL60 cells. This bioimprint-based technology 
can be successfully upscaled and integrated into a medical 
device for depletion of residual myeloblasts from peripheral 
blood of AML patients before and after chemotherapy, with the 
aim of deepening the remission of treated patients and 
reducing minimal residual disease,29 an endpoint associated 
with improved patient outcomes.
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